These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Dematteo RP, Gold JS, Saran L, Gönen M, Liau KH, Maki RG, Singer S, Besmer P, Brennan MF, Antonescu CR. Cancer; 2008 Feb 01; 112(3):608-15. PubMed ID: 18076015 [Abstract] [Full Text] [Related]
7. Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease. An JY, Choi MG, Noh JH, Sohn TS, Kang WK, Park CK, Kim S. Eur J Surg Oncol; 2007 Oct 01; 33(8):1030-5. PubMed ID: 17428635 [Abstract] [Full Text] [Related]
8. Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate. Wu TJ, Lee LY, Yeh CN, Wu PY, Chao TC, Hwang TL, Jan YY, Chen MF. BMC Gastroenterol; 2006 Oct 24; 6():29. PubMed ID: 17062131 [Abstract] [Full Text] [Related]
17. A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence. Higashi D, Watanabe Y, Hirano K, Shimomura T, Egawa Y, Tomiyasu T, Ishibashi Y, Futami K, Maekawa T, Ota A, Oshige K, Iwashita A. Anticancer Res; 2009 Nov 24; 29(11):4893-6. PubMed ID: 20032453 [Abstract] [Full Text] [Related]
19. [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]. Zhan WH, Wang PZ, Shao YF, Wu XT, Gu J, Li R, Wan DS, Ding KF, Shi YQ, Yu JR, Lu HS, Zou XM, Bi JW, Sun YH, Lu YF, Chen DD, Zhang XH. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Sep 24; 9(5):383-7. PubMed ID: 17043955 [Abstract] [Full Text] [Related]